课题基金 / 基金详情

Evaluating patient-reported outcomes for pulmonary nontuberculous mycobacterial disease

Evaluating patient-reported outcomes for pulmonary nontuberculous mycobacterial disease
评估患者报告的肺非结核分枝杆菌疾病的结果
批准号:
10367984
负责人:
Emily M. Henkle
金额:
$14.87万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-03-15 至 2023-05-31
关键词:
AdvocateAntibioticsBeliefBronchiectasisCaringCharacteristicsChronicChronic DiseaseChronic Obstructive Pulmonary DiseaseChronic lung diseaseClinicClinicalClinical TrialsCommon Terminology Criteria for Adverse EventsComplexCoughingDataDecision MakingDevelopmentDiseaseElderlyEnvironmentFatigueFeasibility StudiesFocus GroupsFoundationsFundingGoalsHealth StatusInterventionInterviewLabelLungLung diseasesMacrolidesMeasurementMeasuresMethodsMicrobiologyMycobacterium avium ComplexNational Cancer InstituteOutcomeOutcome MeasureOutcomes ResearchPatient CarePatient MonitoringPatient Outcomes AssessmentsPatient PreferencesPatient Self-ReportPatient-Focused OutcomesPatientsPatternPharmaceutical PreparationsPharmacotherapyPhenotypePhysical FunctionPrincipal InvestigatorProviderPsychometricsQualitative EvaluationsQuality of lifeRandomized Clinical TrialsRandomized Controlled TrialsRare DiseasesRegimenRelapseReportingResearch PriorityRespiratory Signs and SymptomsRiskShortness of BreathSoilSurveysSymptomsTestingTherapeuticTimeToxic effectTreatment-related toxicityValidationWaterWorkacceptability and feasibilitybasecancer clinical trialcancer therapyclinical careclinical practicecomparative effectiveness trialdisabilityeVisiteffective therapyexperiencefuture implementationhealth assessmenthealth related quality of lifeimplementation researchimprovedinsightinterestlongitudinal analysisnon-tuberculosis mycobacteriaolder patientpathogenpatient orientedprospectiverecruitresponsesecondary outcomesuccesstherapy outcometooltreatment responsetrial comparing

项目摘要

项目成果

Emily M. Henkle的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 由鸟分枝杆菌复合体(MAC)引起的肺非结核分枝杆菌(NTM)病是一种 越来越常见的罕见病MAC是存在于土壤和水中的环境病原体, 导致慢性、使人衰弱的肺部疾病,主要发生在有潜在肺部疾病的老年患者中。 有两种不同的表型,更常见的结节性疾病与支气管扩张和较少 常见空洞性疾病伴慢性阻塞性肺病。治疗包括3-5次 标签外抗生素18-24个月。肺MAC难以根除,并且从肺MAC复发或再感染。 环境是共同的。虽然经常实现微生物学反应,但这种结果的能力 反映患者感觉、功能或生存情况的测量方法知之甚少。 在这个应用程序中,我们将扩展我们与NTM患者和患者倡导利益相关者的先前工作, 确定了有意义的PRO指标的开发,并使用健康相关的 生活质量(HRQoL)作为首要研究重点。我们提出的工作采用混合方法, 利用我们的区域NTM转诊诊所和最近启动的前瞻性随机临床试验, 3-肺MAC的药物治疗(MAC 2 v3试验)。Kevin温斯洛普博士是主要研究者, 作为MAC 2 v3试验的协调中心。从NTM诊所招募,我们将首先进行 定性评价NTM模块是否遗漏了非NTM患者的任何特征性NTM症状。 支气管扩张患者(Aim 1a)。我们将在MAC 2 v3试验的治疗患者中进一步验证NTM模块。 MAC 2 v3患者患有结节性支气管扩张MAC(Aim 1b)。在5个时间点收集PRO(基线,1, 3、6和12个月),包括HRQoL和症状(QOL-支气管扩张和NTM模块),以及 症状/毒性(PRO-CTCAE,选择40项)。我们将描述HRQoL的纵向模式, 治疗患者的毒性,并进一步评价毒性与HRQoL随时间的关系(目的2a 和2b)。最后,为了评估在临床实践中纳入PRO的可行性(目标3),我们将重点 与患者和调查临床医生分组,以选择最相关的PRO进行临床护理。试点 实施目标:我们将在温斯洛普医生NTM诊所中纳入一项简短的访视前电子PRO调查, 评价PRO在临床实践中的可行性和可接受性,并描述护理/管理的变化 试点实施后。我们将在第一年完成目标1a,在第二年完成目标1b,在第三年完成目标2a和2b- 4,目标3在第三年。我们预计,我们的工作将产生一个有效的,非结核病特异性PRO, 支持整合到临床实践中的证据。这项工作将为今后的实施奠定基础 NTM患者的PRO和结局研究,从而促进改善复杂的慢性 疾病
英文摘要
PROJECT SUMMARY Pulmonary nontuberculous mycobacterial (NTM) disease due to Mycobacterium avium complex (MAC) is an increasingly common, rare disease. MAC are environmental pathogens present in the soil and water that can cause chronic, debilitating pulmonary disease in predominately older patients with underlying lung disease. There are two distinct phenotypes, more commonly nodular disease associated with bronchiectasis and less commonly cavitary disease with underlying chronic obstructive pulmonary disease. Treatment consists of 3-5 off-label antibiotics for 18-24 months. Pulmonary MAC is difficult to eradicate, and relapse or reinfection from the environment is common. While microbiologic response is frequently achieved, the ability of this outcome measure to reflect how the patient feels, functions, or survives is poorly understood. In this application, we will expand our prior work with NTM patients and patient advocate stakeholders that identified the development of meaningful PRO measures and measuring treatment response using health-related quality of life (HRQoL) as top research priorities. Our proposed work uses a mixed methods approach and leverages our regional NTM referral clinic and recently initiated prospective randomized clinical trial of 2-drug vs. 3-drug therapy for pulmonary MAC (MAC2v3 trial). Dr. Kevin Winthrop is the principal investigator and OHSU serves as the coordinating center for the MAC2v3 trial. Recruiting from the NTM clinic, we will first conduct qualitative evaluation of whether the NTM Module missed any characteristic NTM symptoms in non- bronchiectatic patients (Aim 1a). We will further validate the NTM Module in treated patients in the MAC2v3 trial. MAC2v3 patients have nodular-bronchiectatic MAC (Aim 1b). PROs are collected at 5 time points (baseline, 1, 3, 6, and 12 months), and include HRQoL and symptoms (QOL-Bronchiectasis and NTM Module), and symptoms/toxicity (PRO-CTCAE, selected 40 items). We will describe longitudinal patterns of HRQoL and toxicity in treated patients, and further evaluate the relationship between toxicity and HRQoL over time (Aims 2a and 2b). Last, to evaluate feasibility for incorporating PROs in clinical practice (Aim 3) we will conduct focus groups with patients and survey clinicians to select the most relevant PROs for clinical care. In the pilot implementation aim we will incorporate a brief pre-visit electronic PRO survey in Dr. Winthrop's NTM clinic, evaluating the feasibility and acceptability of PROs in clinical practice and describe changes in care/management after pilot implementation. We will complete Aim 1a during Year 1, Aim 1b in Year 2, Aims 2a and 2b in Years 3- 4, and Aim 3 in Year 3. We anticipate that our work will produce a validated, NTM-disease specific PRO and evidence to support integration into clinical practice. This work will lay the foundation for future implementation and outcomes research of PROs for NTM patients, thus facilitating improved patient care for a complex, chronic disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Patient reported outcomes in patients with nontuberculous mycobacterial pulmonary disease
海外基金